| Literature DB >> 28004511 |
Michael H Sonntag1, Jurgen Schill1, Luc Brunsveld1.
Abstract
The potential of the fluorescent protein scaffold to control peptide sequence functionality is illustrated by an exploration of fluorescent proteins as novel probes for targeting integrins. A library of fluorescent mCitrine proteins with RGD motifs incorporated at several positions in loops within the protein main chain was generated and characterized. Amino acid mutations to RGD as well as RGD insertions were evaluated: both led to constructs with typical mCitrine fluorescent properties. Screening experiments against four human integrin receptors revealed two strong-binding constructs and two selective integrin binders. The effect of the site of RGD incorporation illustrates the importance of the protein scaffold on RGD sequence functionality, leading to fluorescent protein constructs with the potential for selective integrin targeting.Entities:
Keywords: RGD; fluorescent probes; integrin; protein engineering; protein-protein interactions
Mesh:
Substances:
Year: 2017 PMID: 28004511 PMCID: PMC5347895 DOI: 10.1002/cbic.201600514
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164
Figure 1GRGDS insertion sites in mCitrine (PDB ID:1YFP).27
mCitrine‐RGD protein constructs and characteristics.
| GRGDS position | Cloning[a] | Fluorescence[b] | ELISA signal intensity [a.u.] | |
|---|---|---|---|---|
| αvβ3 [c] | αvβ5 [c] | |||
| none | + | 398 | 0.058±0.010 | 0.123±0.003 |
|
| ||||
| N terminus | + | n.a. | 0.137±0.014 | 0.133±0.008 |
| 49/50 | + | 445 | 0.238±0.008 | 0.146±0.006 |
| 78/79 | + | 342 | 0.098±0.002 | 0.142±0.006 |
| 116/117 | + | 425 | 0.332±0.013 | 0.249±0.009 |
| 134/135 | + | n.a. | 0.480±0.050 | 0.136±0.013 |
| 140/141 | + | 393 | 1.60±0.05 | 0.98±0.10 |
| 157/158 | + | 372 | 0.164±0.002 | 0.142±0.001 |
| 172/173 | + | 393 | 0.445±0.024 | 0.180±0.010 |
| 189/190 | + | 377 | 0.313±0.008 | 0.195±0.004 |
| 194/195 | + | 240 | 1.90±0.04 | 0.789±0.025 |
| 213/214 | + | 405 | 0.629±0.054 | 0.135±0.006 |
| C terminus | + | 392 | 0.057±0.010 | 0.142±0.005 |
|
| ||||
| 49/53 | + | 270 | 0.057±0.010 | 0.158±0.003 |
| 78/82 | + | 38 | 0.177±0.006 | 0.483±0.025 |
| 116/121 | + | n.a. | 0.124±0.003 | 0.125±0.003 |
| 135/138 | + | n.a. | 0.64±0.04 | 0.207±0.044 |
| 140/144 | + | n.a. | 0.63±0.02 | 0.439±0.014 |
| 156/160 | + | 479 | 0.244±0.009 | 0.164±0.010 |
| 171/174 | + | 392 | 0.244±0.011 | 0.188±0.030 |
| 190/194 | − | n.d. | n.d. | n.d. |
| 194/198 | + | 235 | 1.158±0.019 | 0.69±0.01 |
| 211/215 | + | 192 | 0.095±0.005 | 0.128±0.009 |
[a]+: successful; −: not successful. [b] Fluorescence intensity (arbitrary units): λ ex=515 nm, λ em=528 nm for 1 μm mCitrine‐RGD in PBS; n.a. not active; n.d. not determined. [c] ELISA signal intensity for two representative integrins. Values are mean±SD (n=3).
Figure 2mCitrine‐RGD variants binding to human integrin receptors αvβ3, αvβ5, α5β1, and α1β1. A) GRGDS sequence inserted at the indicted positions. B) GRGDS substituted for five amino acids at the indicted positions.